EFFICACY OF TREATMENT OF PATIENTS WITH ARTERIAL HYPERTENSION AND COMORBID NON-ALCOHOLIC FATTY LIVER DISEASE

The study aims to analyze the efficacy of prescribing losartan or telmisartan in combination with atorvastatin and ursodeoxycholic acid during the comprehensive treatment of patients with arterial hypertension and
comorbid non-alcoholic fatty liver disease. Material and methods. 65 patients with arterial hypertension and comorbid non-alcohol fatty liver disease were divided into 2 groups. The first group consisted of 26 patients who were prescribed with 50 mg of losartan combined with 20 mg of atorvastatin and 10 mg/kg of ursodeoxycholic acid. The second group consisted of 39 patients who were prescribed with 20 mg of telmisartan combined with 20 mg of atorvastatin and 10 mg/kg of ursodeoxycholic acid. All patients underwent routine physical and laboratory examinations, electro- and echocardiographic diagnostics. Results. It was found that combination of both telmisartan and losartan with atorvastatin and ursodeoxycholic acid in patients with comorbid pathology reduced the level of systolic and diastolic blood pressure, increased left ventricle ejection fraction, decreased the size of the left heart, myocardial mass and left ventricle myocardial mass index. Moreover, the level of proinflammatory interleukin-6 was reduced and the level of adiponectin was increased due to the use of these drugs combinations.

1. Tana C., Ballestri S., Ricci F., Vincenzo A., Ticinesi A., Gallina S., Giamberardino M. A., Cipollone F., Sutton R., Vettor R., Fedorowski A., Meschi T. Cardiovascular Risk in Non-Alcoholic Fatty Liver Disease: Mechanisms and Therapeutic Implications // Int J Environ Res Public Health. 2019. Vol. 16, Is. 17. P. 3104. DOI 10.3390/ijerph16173104.

2. Zhu J.-Z., Hollis-Hansen K., Wan X-Y., Fei S.-J., Pang X.-L., Meng F.-D., Yu C.-H., Li Y.-M. Clinical Guidelines of Non-Alcoholic Fatty Liver Disease: A Systematic Review // World J Gastroenterol. 2016. Vol. 22, Is. 36. P. 8226–8233. DOI 10.3748/wjg.v22.i36.8226.

3. Narayan J., Das H. S., Nath P., Singh A., Mishra D., Padhi P. K., Singh S. P. Endothelial Dysfunction, a Marker of Atherosclerosis, Is Independent of Metabolic Syndrome in NAFLD Patients // Int J Hepatol. 2020. No. 2020. P. 1825142. DOI 10.1155/2020/1825142.

4. Lau L. H. S., Wong S. H. Microbiota, Obesity and NAFLD // Adv Exp Med Biol. 2018. Vol. 1061. P. 111–125. DOI 10.1007/978-981-10-8684-7_9.

5. Cobbina E., Akhlaghi F. Non-Alcoholic Fatty Liver Disease (NAFLD) – Pathogenesis, Classification, and Effect on Drug Metabolizing Enzymes and Transporters // Drug Metab Rev. 2017. Vol. 49, Is. 2. P. 197–211. DOI 10.1080/03602532.2017.1293683.

6. Idalsoaga F., Kulkarni A. V., Mousa О. Y., Arrese M., Arab J. P. Non Alcoholic Fatty Liver Disease and Alcohol-Related Liver Disease: Two Intertwined Entities // Front Med (Lausanne). 2020. Vol. 7. P. 448. DOI 10.3389/fmed.2020.00448.

7. Torre S. D. Non-Alcoholic Fatty Liver Disease as a Canonical Example of Metabolic Inflammatory-Based Liver Disease Showing a Sex-Specific Prevalence: Relevance of Estrogen Signaling // Front Endocrinol (Lausanne). 2020. Vol. 11. P. 572490. DOI 10.3389/fendo.2020.572490.

8. Rinaldi L., Pafundi P. C., Galiero R., Caturano A., Morone M. V., Silvestri C., Giordano M., Salvatore T., Sassо F. C. Mechanisms of Non-Alcoholic Fatty Liver Disease in the Metabolic Syndrome. A Narrative Review // Antioxidants (Basel). 2021. Vol. 10, Is. 2. P. 270. DOI 10.3390/antiox10020270.

9. Shao M., Ye Z., Qin Y., Wu T. Abnormal Metabolic Processes Involved in the Pathogenesis of Non-Alcoholic Fatty Liver Disease (Review) // Exp Ther Med. 2020. Vol. 20, Is. 5. P. 26. DOI 10.3892/etm.2020.9154.

10. Arroyave-Ospina J. C., Wu Z., Geng Y., Moshage H. Role of Oxidative Stress in the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Implications for Prevention and Therapy // Antioxidants (Basel). 2021. Vol. 10, Is. 2. P. 174. DOI 10.3390/antiox10020174.

11. Bovi A. P. D., Marciano F., Mandato C., Siano M. A., Savoia M., Vajro P. Oxidative Stress in Non-Alcoholic Fatty Liver Disease. An Updated Mini Review // Front Med (Lausanne). 2021. Vol. 8. P. 595371. DOI 10.3389/fmed.2021.595371.

12. Alsadoon A., Hassanian M., Alkhalidi H. et al. Endothelial Dysfunction in Nonalcoholic Steatohepatitis with Low Cardiac Disease Risk // Sci Rep. 2020. Vol. 10. P. 8825. DOI 10.1038/s41598-020-65835-y.

13. Valle-Martos R., Valle M., Martos R., Cañete R., Jiménez-Reina L., Cañete M. D. Liver Enzymes Correlate with Metabolic Syndrome, Inflammation, and Endothelial Dysfunction in Prepubertal Children with Obesity // Front Pediatr. 2021. Vol. 9. P. 629346. DOI 10.3389/fped.2021.629346.

14. Arslan U., Yenerçağ M. Relationship Between Non-Alcoholic Fatty Liver Disease and Coronary Heart Disease // World J Clin Cases. 2020. Vol. 8, Is. 20. P. 4688–4699. DOI 10.12998/wjcc.v8.i20.4688.

15. Rosato V., Masarone M., Dallio M., Federico A., Aglitti A., Persico M. NAFLD and Extra-Hepatic Comorbidities: Current Evidence on a Multi-Organ Metabolic Syndrome // Int J Environ Res Public Health. 2019. Vol. 16, Is. 18. P. 3415. DOI 10.3390/ijerph16183415.

16. Marchisello S., Di Pino A., Scicali R., Urbano F., Piro S., Purrello F., Rabuazzo M. A. Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview // Int J Mol Sci. 2019. Vol. 20, Is. 8. P. 1948. DOI 10.3390/ijms20081948.

17. Itier R., Guillaume M., Ricci J.‐E., Roubille F., Delarche N., Picard F., Galinier M., Roncalli J. Non‐Alcoholic Fatty Liver Disease and Heart Failure with Preserved Ejection Fraction: From Pathophysiology to Practical Issues // ESC Heart Fail. 2021. Vol. 8, Is. 2. P. 789–798. DOI 10.1002/ehf2.13222.

18. Borém L. M. A., Neto J. F. R., Brandi I. V., Lelis D. F., Santos S. H. S. The Role of Tangiotensin II Type I Receptor Blocker Telmisartan in the Treatment of Non-Alcoholic Fatty Liver Disease: A Brief Review // Hypertens Res. 2018. Vol. 41, Is. 6. P. 394–405. DOI 10.1038/s41440-018-0040-6.

19. Mantovani A., Dalbeni A. Treatments for NAFLD: State of Art // Int J Mol Sci. 2021. Vol. 22, Is. 5. P. 2350. DOI 10.3390/ ijms22052350.

20. Athyros V. G., Boutari C., Stavropoulos K., Anagnostis P., Imprialos K. P., Doumas M., Karagiannis A. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk // Curr Vasc Pharmacol. 2018. Vol. 16, Is. 3. P. 246–253. DOI 10.2174/1570161115666170621082910.

21. Doumas M., Imprialos K., Dimakopoulou A., Stavropoulos K., Binas A., Athyros V. G. The Role of Statins in the Management of Nonalcoholic Fatty Liver Disease // Curr Pharm Des. 2018. Vol. 24, Is. 38. P. 4587–4592. DOI 10.2174/1381612825666190117114305.

22. Mikami K., Endo T., Sawada N., Igarashi G., Kimura M., Hasegawa T., Iino C., Tomita H., Sawada K., Nakaji S., Matsuzaka M., Torok N., Fukuda S. Leptin/Adiponectin Ratio Correlates with Hepatic Steatosis but Not Arterial Stiffness in Nonalcoholic Fatty Liver Disease in Japanese Population // Cytokine. 2020. Vol. 126. P. 154927. DOI 10.1016/j. cyto.2019.154927.

23. Рекомендации ЕSC/EAS по лечению дислипидемий: модификация липидов для снижения сердечно-сосудистого риска. 2019 // Рос. кардиол. журн. 2020. № 25 (5). С.121–193. DOI 10.15829/1560-4071-2020-3826.

24. Фeдорова Т. А., Иванова Е. А., Семененко Н. А., Ройтман А. П., Тазина С. Я., Лощиц Н. В., Рыбакова М. К. Клинико-лабораторные аспекты хронической сердечной недостаточности у больных метаболическим синдромом // Эффективная фармакотерапия. 2019. Т. 15, № 20. С. 10–16. DOI 10.33978/2307-3586-2019-15-20-10-16.

25. Ткаченко Л. И., Малеев В. В. Роль системного воспаления в патогенезе инсулинорезистентности и метаболического синдрома у больных хроническим гепатитом С // Терапевтический архив. 2018. № 11. С. 24–31. DOI: https://doi.org/10.26442/terarkh201890114-31.

26. Беляева О. Д., Бровин Д. Л., Березина А. В., Каронова Т. Л., Чубенко Е. А., Баранова Е. И., Беркович О. А. Уровень общего и высокомолекулярного адипонектина у женщин с абдоминальным ожирением и артериальной гипертензией // Артериальная гипертензия. 2014. Т. 20, № 5. С. 43–50. DOI: https://doi.org/10.18705/1607-419X-2014-20-5-442-449.